Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Open accessThe DOI matches its Crossref record; 24 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million people with HIV/AIDS in developing countries. METHODS: Four HCV DAAs, currently either in phase 3 development or recent approval (daclatasvir, sofosbuvir, simeprevir, faldaprevir), and ribavirin were classified by chemical structure, molecular weight, total daily dose, and complexity of synthesis. The likely range of manufacturing costs per gram of DAA were then projected as formulated product cost, based upon treating a minimum of 1 million patients annually (to arrive at volume demand) combined with an analysis of the complexity of synthesis and a 40% margin for formulation. Projections were then compared with actual costs of antiretrovirals with similar structures. RESULTS: Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram. The complexity of chemical synthesis for HCV DAAs was ranked from lowest to highest: ribavirin, daclatasvir, sofosbuvir, faldaprevir, and simeprevir. Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21-$63 for ribavirin, $10-$30 for daclatasvir, $68-$136 for sofosbuvir, $100-$210 for faldaprevir, and $130-$270 for simeprevir. CONCLUSIONS: Within the next 15 years, large-scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100-$250 per 12-week treatment course. These low prices could make widespread access to HCV treatment in low- and middle-income countries a realistic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our methodology for calculating drug EMPs has previously accurately predicted how low medication prices can go when they are produced generically [31]; however, this methodology is based on multiple assumptions.”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with cost-based pricing research similar to this, alongside advocacy groups and political will, treatment courses were brought down to <$100 per 12-week treatment course [31,40].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“when direct-acting antivirals were developed for hepatitis C 10 years ago, courses were $84,000 per person ($1000/pill)”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515 · cited 1×
“Worldwide, 160–180 million people are antibody positive for Hepatitis C, with up to 500 000 HCV-related deaths per year [1, 2].”
BackgroundEvolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090 · cited 2×
“Sofosbuvir + RBV POSITRON [15] (n = 207 + 71 placebo) IFN-ineligible 2 12 wk (n = 109) 93% (SVR-12)”
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“Daclatasvir has a straightforward synthesis with the cost-limiting intermediate being the substituted biphenyl compound shown (Table 5) [21, 22].”
BackgroundThe WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
Gilks, C. F., Crowley, S., Ekpini, R., Gove, S., Perriens, J., Souteyrand, Y., Sutherland, D., Vitoria, M., Guerma, T., & De Cock, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69158-7 · Cited by 689 · cited 1×
“proaches using tolerable, easy-to-administer regimens that are supportive of task shifting (care delivery by lesser trained health staff ) and good patient adherence, and could be facilitated by widespread access to oral, short-course DAA therapy in lowincome countries [29].”
BackgroundWitkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471 · cited 1×
“Analysis revealed that ribavirin has a relatively simple chemical synthesis [20].”
BackgroundLow-cost tools for diagnosing and monitoring HIV infection in low-resource settings
Wu, G., & Zaman, M. H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.12.102780 · Cited by 190
The global health burden of hepatitis C virus infection
Negro, F., & Alberti, A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02537.x · Cited by 181 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Moon, S., Jambert, E., Childs, M., & von Schoen-Angerer, T. (2011) · Globalization and Health · doi:10.1186/1744-8603-7-39 · Cited by 138
Research works printed but not linked: 5
- 2013, Journal of hepatology, 58, S22
- 2012, Clinical Infectious Diseases, 54, 145
- 2012, Hepatology (Baltimore, Md.), 56, 230A
- 2012, Hepatology (Baltimore, Md.), 56, 306A
- 2012, Hepatology (Baltimore, Md.), 56, 308A
Cited by
Items 101–200 of 242
Matičič, M., Zorman, J. V., Gregorčič, S., Schatz, E., & Lazarus, J. V. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-s6-s14 · Cited by 18
“Unfortunately, the extremely high prices of the new direct acting antivirals (DDAs) will limit their availability in many European countries [75,76].”
BackgroundWhat does it mean to put new hepatitis C drugs on a list of essential medicines?
Urrutia, J., Porteny, T., & Daniels, N. (2016) · BMJ · doi:10.1136/bmj.i2035 · Cited by 18
Hepatitis C eradication: A long way to go
Waheed, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12510 · Cited by 17
Read, S. A., Tay, E. S. E., Shahidi, M., McLauchlan, J., George, J., & Douglas, M. W. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0209 · Cited by 17
Ishida, Y.-I., Takeshita, M., & Kataoka, H. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i12.870 · Cited by 17
Magrì, A., Ozerov, A. A., Tunitskaya, V. L., Треворович, В.-Э. В., Wahid, A. M., Pirisi, M., Peter Simmonds, K., Ivanov, A. V., Novikov, M. S., & Patel, A. H. (2016) · Scientific Reports · doi:10.1038/srep29487 · Cited by 17
Graham, C. S. (2020) · Clinical Liver Disease · doi:10.1002/cld.925 · Cited by 16
Kramer, M., Halleran, D., Rahman, M., Iqbal, M., Anwar, M. I., Sabet, S., Ackad, E., & Yousef, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104425 · Cited by 16
“Although Simeprevir and Sofosbuvir provide a way to treat multiple genotypes of HCV, the cost of the typical 3 month treatment ($66,000 and $84,000 respectively), is too expensive for use in developing countries [38,39].”
BackgroundSood, N., Ung, D., Shankar, A., & Strom, B. L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0186 · Cited by 16
Outcomes, costs and cost–effectiveness of treating hepatitis C with direct acting antivirals
Stahmeyer, J. T., Rossol, S., & Krauth, C. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.13 · Cited by 15
“Hill et al. (2014) estimated the production costs of different DAA regimens to be at $78–$454 for a 12-week treatment course [82].”
BackgroundBarriers to access to hepatitis C treatment
Yılmaz, H., Yılmaz, E. M., & Leblebicioğlu, H. (2016) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.7849 · Cited by 15
Birger, R. B., Le, T. P., Kouyos, R. D., Grenfell, B. T., & Hallett, T. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177195 · Cited by 15
Indian hepatitis C drug patent decision shakes public health community
Hoen, E. ‘. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30656-0 · Cited by 15
Presence of bovine hepacivirus in Turkish cattle
Yeşilbağ, K., Baechlein, C., Kadiroğlu, B., Toker, E. B., Aytoğu, G., & Becher, P. (2018) · Veterinary Microbiology · doi:10.1016/j.vetmic.2018.09.001 · Cited by 15
Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism
Spaulding, A. C., Chhatwal, J., Adee, M. G., Lawrence, R., Beckwith, C. G., & von Oehsen, W. H. (2018) · Journal of Correctional Health Care · doi:10.1177/1078345818805770 · Cited by 15
Chan, S., Isbel, N. M., Hawley, C. M., Campbell, S. B., Campbell, K. L., Morrison, M., Francis, R. S., Playford, E. G., & Johnson, D. W. (2019) · Medicina · doi:10.3390/medicina55100672 · Cited by 15
Ooms, G., Forman, L., Williams, O. D., & Hill, P. (2014) · BMC International Health and Human Rights · doi:10.1186/s12914-014-0037-4 · Cited by 15
“So far, our proposal was based on the assumption that the price for Belgium is indeed reasonable, and can be used to calculate reasonable tiered pricing for developing countries, which may not be the case for all new medicines [19].”
BackgroundHepatitis C cross-genotype immunity and implications for vaccine development
Islam, N., Krajden, M., Shoveller, J., Gustafson, P., Gilbert, M., Wong, J., TYNDALL, M. W., Janjua, N. Z., The BC-HTC Team, Yu, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10190-8 · Cited by 14
Taye, B. W. (2019) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.19-0295 · Cited by 14
“ulatory support helps the procurement of DAAs essential to treat HCV by enabling the acquisition of pan-genotypic regimens to ensure access to the broader population.(27,34,59)”
BackgroundMolecular characterization of Hepatitis C virus 3a in Peshawar
Gul, A., Zahid, N., Ahmed, J., Zahir, F., Khan, I. A., & Ali, I. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1488-0 · Cited by 14
“An estimated 185 million people (3 % of the world’s population) are infected worldwide with relatively high prevalence rates in developing countries [3, 4].”
BackgroundEmerging Trends in Clinical Research With Implications for Population Health and Health Policy
Chin-Yee, B. H., Subramanian, S. V., Verma, A. A., Laupacis, A., & Razak, F. A. (2018) · Milbank Quarterly · doi:10.1111/1468-0009.12328 · Cited by 13
Nabulsi, N. A., Martin, M. T., Sharp, L. K., Koren, D. E., Teply, R. M., Zuckerman, A. D., & Lee, T. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.551500 · Cited by 13
“In low- and middle-income countries, where the majority of patients with HCV reside and issues of overall affordability still prevent utilization, treatment failure prediction models may also be less relevant (Hill et al., 2014; Phelan and Cook, 2014; Andrieux-Meyer et al., 2015; Zoulim et al., 2015; Lanini et al., 20…”
BackgroundValuing Cure: Bridging Cost-Effectiveness and Coverage Decisions for Hepatitis C Therapy
Pho, M. T., & Linas, B. P. (2014) · Hepatology · doi:10.1002/hep.27220 · Cited by 13
“Based on wholesale acquisition costs for SOF and SMV, overall costs for a treatment course has reached $100,000-$250,000 per person.(3) This pricing has provoked outrage from hepatitis C advocates and the community in general.”
BackgroundAdvances in interferon-free hepatitis C therapy: 2014 and beyond
Sarkar, S., & Lim, J. K. (2014) · Hepatology · doi:10.1002/hep.27055 · Cited by 12
Personalized care approaches to hepatitis C therapy: recent advances and future directions
Moriello, N. S., Pinchera, B., & Gentile, I. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2328336 · Cited by 12
Lamoury, F. M. J., Njouom, R., Amougou‐Atsama, M., Mfopou, E. Y., Berishvili, N., Sologashvili, M., Fajardo, E., Malobela, A., Macé, A., Chirehwa, M., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11050746 · Cited by 12
Medicines Pricing: Limitations of Existing Policies and New Models
Vogler, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-2724-1_5 · Cited by 11
Synthetic Routes to Sofosbuvir
Barth, R., Rose, C. A., & Schöne, O. (2015) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_183 · Cited by 11
Zhang, B., Nguyen, N. H., Yee, B. E., Yip, B., Ayoub, W. S., Lutchman, G. A., & Nguyen, M. H. (2015) · Intervirology · doi:10.1159/000437427 · Cited by 11
(2014) · Nature Medicine · doi:10.1038/nm.3538 · Cited by 11
Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant
Herzer, K., Papadopoulos-Köhn, A., Achterfeld, A., Canbay, A., Piras-Straub, K., Paul, A., Walker, A., Timm, J., & Gerken, G. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i9.1287 · Cited by 10
Returns on social development initiatives of MNEs: issues and perspectives
Gupta, S. (2017) · Qualitative Market Research An International Journal · doi:10.1108/qmr-01-2017-0004 · Cited by 10
“purchasing ability, 3) markets that provide skilled labour required to perform business and 4) markets that provide a network of sellers to facilitate penetration with or without the help of technology. Using stakeholder views of MNE performance in these areas and considering intellectual capital as a resource used by…”
BackgroundInfluentialProuté, M., Cœur, S. L., Tiv, M., Dub, T., Jongpaijitsakul, P., Ratnamhin, A., Angkurawaranon, C., Aramrattana, A., & Lallemant, M. J. (2020) · BMC Public Health · doi:10.1186/s12889-020-09549-w · Cited by 9
Grignard Reagents as Niche Bases in the Synthesis of Pharmaceutically Relevant Molecules
Samineni, R., Eda, V. V. R., Rao, P., Sen, S., & Oruganti, S. (2022) · ChemistrySelect · doi:10.1002/slct.202102853 · Cited by 9
Gelband, H., Chen, C., Chen, W., Franceschi, S., Hall, S. A., London, W. T., McGlynn, K. A., & Wild, C. P. (2015) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0349-9_ch8 · Cited by 9
Gene therapy: a possible future standard for HIV care
Abou‐El‐Enein, M., Bauer, G., & Reinke, P. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.03.006 · Cited by 8
Papadopoulos-Köhn, A., Achterfeld, A., Paul, A., Canbay, A. E., Timm, J., Jochum, C., Gerken, G., & Herzer, K. (2014) · Transplantation · doi:10.1097/tp.0000000000000399 · Cited by 8
“resistance and with respect to cost, which will be a limitation for the administration of novel DAAs for the treatment and eradication of HCVin less-developed or economically poorer countries.(25,26)”
BackgroundAi, T., Qiu, L., Xie, J., Geraghty, R. J., & Chen, L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.035 · Cited by 8
Vogler, S. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_7 · Cited by 8
The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam
Nguyen, H. A., Cooke, G., Day, J., Flower, B., Phuong, L. T., Hung, T. M., Dung, N. T., Khoa, D. B., Hung, T. M., Kestelyn, E., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15408.2 · Cited by 8
Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model
Lagaye, S., Brun, S., Gaston, J., Shen, H., Stránská, R., Camus, C., Dubray, C., Rousseau, G., Massault, P. P., Courcambeck, J., et al. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i21.902 · Cited by 8
Daclatasvir for the treatment of hepatitis C virus infection
Adler, H., & Lambert, J. S. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.925798 · Cited by 7
“One analysis predicted that, assuming standard market dynamics apply and third-party manufacturing licenses are granted, a 12-week course of DCV would cost US$10–30 with a 12-week course of SOF costing US$68–136 [63].”
BackgroundSeu, R., Riback, L. R., Nyakowa, M., Lizcano, J. A., Musyoki, H., Ross, J., Cherutich, P., Kurth, A., & Akiyama, M. J. (2022) · Global Public Health · doi:10.1080/17441692.2022.2110919 · Cited by 7
“As perWHO guidance, (Easterbrook & Group, 2016) consideration should be made to tailor such guidelines in LMICs to account for specific structural challenges, such as high testing costs and variable numbers of laboratories available for HCV testing as well as uneven access and affordability of DAA treatment (Graham &…”
BackgroundEuroCoord, T. U. E. C. S. I., Bailey, H., Nizova, N., Martsynovska, V., Volokha, A. P., Malyuta, R., Cortina‐Borja, M., & Thorne, C. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-2089-7 · Cited by 7
“However, the high cost of DAAs currently limits access, particularly in low and middle income countries [15].”
BackgroundAssessment of External Price Referencing and Alternative Policies
Vogler, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813166-4.00019-x · Cited by 7
Conti, J., Dryden, E. M., Fincke, B. G., Dunlap, S. W., & McInnes, D. K. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07708-w · Cited by 7
Sultanik, P., Mallet, V. O., Lagaye, S., Casrouge, A., Dorival, C., Barthe, Y., Fontaine, H., Hézode, C., Mottez, E., Bronowicki, J., et al. (2015) · Liver International · doi:10.1111/liv.12759 · Cited by 6
“The economic issues related to treatment access has been projected to continue over the next years, as suggested by the estimation that producing these new drugs in large-scale treatment access programme in developing countries would take 15 years (4, 5).”
BackgroundRavinetto, R., Weggheleire, A. D., Dorlo, T. P. C., Francque, S., An, S., Pouget, C., Meessen, B., Tabernero, P., Newton, P. N., & Lynen, L. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12784 · Cited by 6
“Conversely, generic competition coupled to economies of scale could dramatically lower prices: a generic version of sofosbuvir is already available at less than US$ 500 per treatment course, and scaled-up manufacturing is projected to achieve target prices of US$ 100–250 for a full generic treatment course within the…”
BackgroundVandegrift, K. J., Critchlow, J. T., Kapoor, A., Friedman, D. A., & Hudson, P. J. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.07.031 · Cited by 6
Epidemiology of viral hepatitis in the Republic of Congo: review
Linguissi, L. S. G., & Nkenfou, C. N. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2951-8 · Cited by 6
“Treatment is now being done using antiretrovirals for HIV control that also act on hepatitis B [41, 42].”
BackgroundPourquoi les nouveaux médicaments sont-ils si chers ?
Galès, C. L. (2018) · médecine/sciences · doi:10.1051/medsci/20183404017 · Cited by 6
“Concernant le Sofosbuvir, pour le traitement de l’hépatite C, le coût de production de la quantité nécessaire à une personne serait compris entre 68 et 136 dollars [11], bien en deçà donc du prix auquel elle est vendue aux États-Unis ou en France, même si le coût de production n’est, bien sûr, pas le seul composant en…”
BackgroundGreenberg, A., & Kiddell‐Monroe, R. (2016) · Globalization and Health · doi:10.1186/s12992-016-0190-8 · Cited by 6
“US$63 per 12-week treatment course [8].”
Doing the math on hepatitis C virus treatment
Mehta, S. H., & Thomas, D. L. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.015 · Cited by 6
“Hill calculated that it costs $10$30 to make daclatasvir and $68-$136 for sofosbuvir, two of the new HCV treatments whose AWP in the USA is almost $1000 USD per pill [17].”
BackgroundScaling‐up HCV treatment to achieve WHO targets by 2030
Cooke, G. (2017) · Tropical Medicine & International Health · doi:10.1111/tmi.12837 · Cited by 6
“Nonetheless, it is reasonable to expect prices for these drugs in LMIC to approach the targets predicted by detailed analysis of the processes required for manufacture [11, 12].”
BackgroundSchaerer, V., Haubitz, S., Kovari, H., Ledergerber, B., Ambrosioni, J., Cavassini, M. L., Stoeckle, M. P., Schmid, P., Decosterd, L. A., Aouri, M., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12269 · Cited by 5
Maier, M. M., Zhou, X., Chapko, M. K., Leipertz, S. L., Wang, X., & Beste, L. A. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-4956-0 · Cited by 5
“The estimated manufacturing cost for 12 weeks of sofosbuvir is only $68–$136 [7].”
BackgroundBereczky, T. (2020) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2019.292 · Cited by 5
Hellard, M. E., & Scott, N. (2015) · Addiction · doi:10.1111/add.12912 · Cited by 4
Scaling up HCV treatment in resource-limited countries
Lemoine, M., & Thursz, M. R. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.31 · Cited by 4
Setting a Public Health Agenda to Support Access to High-Cost Medicines
Yamabhai, I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811945-7.00005-1 · Cited by 4
Tenni, B. F., Lexchin, J., Akaleephan, C., Kittitrakul, C., & Gleeson, D. (2024) · Globalization and Health · doi:10.1186/s12992-024-01053-9 · Cited by 4
“In contrast, a study from 2014 estimated the manufacturing cost of a 12-week course of sofosbuvir to be US$68–US$136 [27].”
BackgroundTulchinsky, T. H., & Varavikova, E. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-415766-8.00016-1 · Cited by 4
Approachability to the New anti-HCV Direct Acting Antiviral Agents in the Latin American Context
Lozano-Sepúlveda, S. A., Bryan-Marrugo, O. L., Merino-Mascorro, J. Á., & Rivas, A. (2015) · Future Virology · doi:10.2217/fvl.15.97 · Cited by 4
Faleiros, D. R., da Silva, E. N., Santos, A. C., Godman, B., Pereira, R. G., & Guerra, A. A. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2057950 · Cited by 4
“tially a cure for an infectious disease with estimates of gross profit levels at 99%, although lower in countries such as Brazil through public negotiations [39,41,42].”
BackgroundTreating Hepatitis C Prior to Total Hip Arthroplasty is Cost-effective: A Markov Analysis
Anoushiravani, A. A., Kalyanasundaram, G., Feng, J. E., Congiusta, F., Iorio, R. R., & DiCaprio, M. R. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.02.067 · Cited by 4
Hepatitis C Medicines: Technology and Market Landscape
Mike, I., Ridzon, R., & Timmermans, K. (2015) · Cited by 4
Perfect, C., & Jhaveri, R. R. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz069 · Cited by 4
Cross, S., Levi, J., Venter, F., & Hill, A. M. (2026) · AIDS · doi:10.1097/qad.0000000000004487 · Cited by 3
Self-citationGari, M. H., Alsuhibani, A. A., Alashgar, A., & Guo, J. J. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100383 · Cited by 3
“44 However, high drug prices are primarily due to government-granted exclusivity and free-market pricing, with medication prices in the US 256% higher in 2018 than 32 other countries combined, and the average net price of brand-name medications in Medicaid increasing from 147 to 218 USD be-tween…”
BackgroundColombo, C., Caldara, D., & Banzi, R. (2024) · Health Expectations · doi:10.1111/hex.14005 · Cited by 3
“The presentation included three sections: 29 The team selected the sources to give the participants balanced information, providing data from different viewpoints (an independent medical journal, academic researchers and pharmaceutical industries).”
BackgroundCozen, M. L., Ryan, J. C., Shen, H., Cheung, R. C., Kaplan, D. E., Pocha, C., Bräu, N., Aytaman, A., Schmidt, W. N., Pedrosa, M. C., et al. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4122-5 · Cited by 3
Abadie, R. (2017) · Narrative Inquiry in Bioethics · doi:10.1353/nib.2017.0019 · Cited by 3
Prescription for the People: An Activist’s Guide to Making Medicine Affordable for All
Quigley, F. (2018) · Cornell University Press eBooks · doi:10.1515/9781501713910 · Cited by 3
Hepatitis awareness among the general public in Cameroon: A survey study
Patil, A., Foguito, F., Balasubramanian, G. V., Flore, N., Patrick, E. P., & Gowda, A. (2014) · International journal of innovation and applied studies · Cited by 3
Mobilising a global response to hepatitis: Lessons learned from the HIV movement
Taaffe, J. E., & Wilson, D. P. (2016) · Global Public Health · doi:10.1080/17441692.2016.1233989 · Cited by 3
Mortazavi, S., Laine, I., Teplov, R., Väätänen, J., & Gupta, S. (2019) · Contributions to management science · doi:10.1007/978-3-030-11766-5_4 · Cited by 3
Vacuna terapéutica contra el virus de la hepatitis C en la era de los antivirales de acción directa
Guridi, Z. D., Dueñas‐Carrera, S., Arús, E., Castellanos, M., & Cinza, Z. (2015) · Biotecnología aplicada · Cited by 2
Tulchinsky, T. H., Varavikova, E. A., & Cohen, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822957-6.00002-8 · Cited by 2
The global economic burden of digestive tract diseases and cancers from 2020 to 2050
Huang, X., Zhang, Q., Cui, H., Li, Z., Zhang, J., Song, Y., Chen, J., Chen, G., Lin, X., Li, X., et al. (2026) · Nature Health · doi:10.1038/s44360-026-00113-1 · Cited by 2
“Hepatitis C direct-acting antivirals achieve over 95% cure rates 14 , with treatment costs substantially reduced in many low-and middle-income countries, making elimination economically feasible 35 .”
Enitan, S. S., Soboyejo, P. H., Digban, K. A., Iduh, M. U., Asekun-Olarinmoye, I. O., Azike, C. A., Itodo, G. E., Adole, A. R., & Okuneye, A. O. (2024) · Avicenna Journal of Clinical Microbiology and Infection · doi:10.34172/ajcmi.3563 · Cited by 2
El-Bastawissy, E. A., & Hassab, M. A. E. (2015) · Drug Designing Open Access · doi:10.4172/2169-0138.1000124 · Cited by 2
“While Vaniprevir was not effective in genotype 4a and despite the treatment option provided by Simeprevir and Paritaprevir the cost of treatment is very high to be afforded by developing countries as the treatment by Simeprevir for three months costs $66,000 [35,36] and the work done to Develop inhibitors for genotype…”
BackgroundLankford, G. B. (2016) · NCSU Libraries Repository (North Carolina State University Libraries) · Cited by 2
Variable Market Exclusivity Periods for Pharmaceuticals
Hsu, M., Thaver, A. M., & Anderson, G. F. (2016) · Health Economics & Outcome Research Open Access · doi:10.4172/2471-268x.1000111 · Cited by 2
“The cost of manufacturing Sovaldi is relatively low – with estimates being $68$136 for a 12 week course of treatment [6].”
BackgroundDurante‐Mangoni, E., Parrella, A., Iossa, D., Andini, R., Molaro, R., Battimelli, C., Sodano, G., & Utili, R. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0241-y · Cited by 2
“Whether this could affect response-guided treatment decision making, as well as triple drug regimens, needs to be further assessed, as peg-IFN use will likely still be required because of specific patient conditions or the need to reduce costs [23].”
BackgroundHilgenfeldt, E., & Firpi, R. J. (2015) · InTech eBooks · doi:10.5772/60986 · Cited by 2
“In the long run, this issue should continue to fade in its controversy given that the minimum manufacturing costs for producing direct acting antivirals have been estimated at $100-250 for a 12-week course of treatment once patent expires and production of generic versions are widely available [14].”
BackgroundMonopoly and public health in the medication market: The case of sofosbuvir
Piergentili, P. (2017) · Journal of Generic Medicines The Business Journal for the Generic Medicines Sector · doi:10.1177/1741134317705691 · Cited by 2
Sofosbuvir: A Potential Treatment for Ebola
Reznik, S. E., Tiwari, A. K., & Ashby, C. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01139 · Cited by 2
“Furthermore, it has been estimated that based upon (1) the manufacturing cost of retroviral drugs with similar mechanisms of action and chemical structures and (2) treating aminimumof 1 million people (Hill et al., 2014), a 12-week regimen of sofosbuvir should cost $68–136, or $23–45 for 4 weeks.”
BackgroundAnalysis of Medicare Expenditure for Discarded Infused Cancer Therapeutics From 2017-2020
Desai, A. P., Xiao, A. H., Smith, C. J., Jensen, C. J., Pritchett, J. C., Soefje, S. A., Durani, U., Go, R. S., Scheckel, C., Jensen, C. J., et al. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.07.026 · Cited by 2
When are effective medications just too expensive?
Mehta, S. J., & Asch, D. A. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.14010 · Cited by 2
Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical ObesityPreprint
Levi, J., Wang, J., Venter, F., & Hill, A. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4068270 · Cited by 2
Self-citationChahal, J. (2020) · doi:10.82308/45570 · Cited by 2
Spending and Pricing to Deter Arbitrage
Salant, S. W. (2024) · The Economic Journal · doi:10.1093/ej/ueae023 · Cited by 1
Reconciling the Paradox of Value-Based Drug Pricing
Poulsen, G., & Liljenquist, D. (2025) · NEJM Catalyst · doi:10.1056/cat.25.0278 · Cited by 1
Ushering a New Era in the Management of Hepatitis C in Children with Hematological Disorders
Sivasankaran, M., Venkatadesikalu, M., Mythili, V., Sankaranarayanan, S., Jayaraman, D., Patel, S., Swaminathan, V. V., Uppuluri, R., & Raj, R. (2018) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-018-0981-6 · Cited by 1
Iduh, M. U., Kuta, F. A., Abalaka, M. E., & Shitu, K. O. (2019) · Journal of BioMedical Research and Clinical Practice · doi:10.46912/jbrcp.100 · Cited by 1
Couri, T., & Aronsohn, A. I. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.024 · Cited by 1
Aston, P. J., Cranfield, K., O’Farrell, H., Cassenote, A. J. F., Mendes-Correa, C. J., Segurado, A. A. C., Hoang, P., Lankford, G. B., & Tran, H. T. (2018) · InTech eBooks · doi:10.5772/intechopen.75761 · Cited by 1
ANTIVIRAL TREATMENT OF CHRONIC HEPATITISС: AVAILABLE RESULTS AND FUTURE PROSPECTS
Мицура, В. М., Красавцев, Е. Л., Жаворонок, С. В., Воропаев, Е. В., Осипкина, О. В., Солдатенко, О. В., Baryash, T. M., & Tsereshkov, D. V. (2017) · Health and Ecology Issues · doi:10.51523/2708-6011.2017-14-1-6 · Cited by 1
Treating Hepatitis C Before Total Knee Arthroplasty is Cost-Effective: A Markov Analysis
Kalyanasundaram, G., Feng, J. E., Congiusta, F., Iorio, R. R., DiCaprio, M. R., & Anoushiravani, A. A. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.08.053 · Cited by 1
Ullah, S., Naveed, M., Ali, A., Bibi, S., Idrees, W., Rafique, S., Idrees, M., Waqas, M. S., Uddin, J., Jan, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24581 · Cited by 1
“A high rate of SVR is reported for daclatasvir after completion of HCV therapy [10].”
Background
Metadata
- Authors
- Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N.
- Affiliations
- University of Liverpool (GB)
- Howard University (US)
- Imperial College London (GB)
- University of Cape Town (ZA)
- Corresponding author
- Hill, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-06
- Volume
- 58
- Issue
- 7
- Pages
- 928-936
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC3952605
- OpenAlex
- W2163848297
- Semantic Scholar
- 777a83aedceb6c84d3ff7d4176d38d6c2613d4a5
- Cited by
- 216
- References
- 28
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 8 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 26 · 2016: 34 · 2015: 43 · 2014: 24
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- hepatitis C, direct-acting antivirals, cost projections, daclatasvir, sofosbuvir, simeprevir, faldaprevir, ribavirin, generic drug production, treatment access, low- and middle-income countries, drug pricing
- MeSH terms
- Sofosbuvir, Simeprevir, Aminoisobutyric Acids, Antiviral Agents, Carbamates, Developing Countries, Drug Industry, Drug Therapy, Combination, Health Services Accessibility, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, Leucine, Oligopeptides, Proline, Pyrrolidines, Quinolines, Ribavirin, Sulfonamides, Thiazoles, Uridine Monophosphate, Valine, Hepacivirus, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.